Comparing Salivary Mir-125 And Mir-30 Expression In Oral Squamous Cell Carcinoma To Healthy Individuals
-
Naghmeh Bahrami
,
Marziyeh Poorahmad
,
Farzaneh Hosseini
,
Farnoush Mohammadi
,
Amir Rasouli
,
Mona Mohajeri Tehrani
,
Masoume Farhangiyan
,
Abdolreza Mohamadnia
Abstract
Introduction: OSCC (Oral squamous cell carcinoma) accounts for approximately 90% of all oral malignancies and is usually diagnosed at advanced stages. This study investigates changes in miR-125 and miR-30 expression in relation to the clinical findings of oral cavity cancer and their possible use as an early diagnostic tool.Method and Material: A population of 30 individuals with oral squamous cell carcinoma and 30 healthy individuals was studied, and the mean age of two groups were compared using a t-test, with no significant difference found in terms of age so age will not be an interfering factor in this study. The levels of these two biomarkers (miR-125 and miR-30) were measured and evaluated using real-time PCR technique.Results: After evaluating the results of real-time PCR technique, it was found that miR-125 was positive in 25 out of 30 patients, while it was positive in 5 out of 30 healthy individuals (p-value ≤0.001). miR-30 was a positive biomarker in 10 out of 30 patients. The amount of this biomarker in the group of healthy individuals was 26 out of 30 (p-value < 0.001).CONCLUSION: The miR-125 profile is upregulated in the saliva of OSCC cases, whereas the miR-30 profile is downregulated in the aforementioned patients compared with the healthy group. Therefore, measurement of miR-125 and miR-30 may be a protentional diagnostic test to identify OSCC. We suggest more extensive studies with a larger sample size to support this claim.Keywords: oral squamous cell carcinoma, miR-125, miR-30, biomarker
1. Nevile B, Douglas D, CARL M, Jerry E. Oral & maxillofacial pathology. 2nd ed. W B South Carolina Saunders Co; 2002. P. 356.
2. Yu-Jen J, Chia-Der L, Chin-Ho L, Chih-Hsin T, Su-Hua H, Ming-Hsui T, et al. Salivary zinc finger protein 510 as a novel biomarker for detection of oral squamous cell carcinoma early stages. Clin Chim Acta. 2011 Jul 15; 412(15-16):1357-65.
3. Jou YJ, Lin CD, Lai CH, Chen CH, Kao JY, Chen SY, et al. Proteomic identification of salivary transferin as a biomarker for early detection of oral cancer. Anal Chim Acta. 2010 Nov 29; 681(1-2):41-8.
4. Nafisa Momeni. What is the treatment of oral Cancer? 1393. Available at: URL: http://www.dandane.ir/. Accessed Jan 10, 2017.
5. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nature reviews Molecular cell biology. 2005;6(5):376-85.
6. Lodish, H., et al. (2008). Molecular cell biology, Macmillan.
7. Chen J, Fu X, Wan Y, Wang Z, Jiang D, Shi L. miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. Tumour Biol. 2014;35 (7):6293–6302. doi:10.1007/s13277-014-1821-4.
8. Liu Z, Smith KR, Khong HT, et al. miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20. Oncotarget. 2016;7(48):78667–78679. doi:10.18632/oncotarget.12018.
9. Wang J, Paris PL, Chen J, et al. Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high gradeinvasive lesions. Cancer Lett. 2015;356(2):404-409.
10. Kandimalla R, Gao F, Matsuyama T, et al. Genome-wide discovery and identification of a novel miRNA signature for recurrence prediction in stage II and III colorectal cancer. Clin Cancer Res. 2018;24(16):3867-3877.
11. Gaziel-Sovran A, Segura MF, Di Micco R, et al. MiR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell. 2011;20(1):104-118
12. LI, C. I., URIBE, D. J., DALING, J. R. (2005). Clinical characteristics of different histologic types of breast cancer. British Journal of Cancer. 93(9), 1046-1052.
13. Pende, M., et al. (2004). "S6K1-/-/S6K2-/- mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogenactivated protein kinase-dependent S6 kinase pathway." Molecular and cellular biology 24(8): 3112-3124.
14. Sebolt-Leopold JS (June 2008). "Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway". Clin. Cancer Res. 14 (12): 3651–6. doi:10.1158/1078-0432.CCR-08-0333. PMID 18559577
15. Radhika T, Jeddy N, Nithya S, Muthumeenakshi RM. Salivary biomarkers in oral squamous cell carcinoma - An insight. J Oral Biol Craniofac Res. 2016 Nov;6(Suppl 1):S51-S54.
16. SUN, Yu-Meng; LIN, Kang-Yu; CHEN, Yue-Qin. Diverse functions of miR-125 family in different cell contexts. Journal of hematology & oncology, 2013, 6: 1-8.
17. Ghosh RD, Pattatheyil A, Roychoudhury S. Functional Landscape of Dysregulated MicroRNAs in Oral Squamous Cell Carcinoma: Clinical Implications. Front Oncol. 2020 May 12;10:619
18. Ma, J.; Fu, Y.; Tu, Y.Y.; Liu, Y.; Tan, Y.R.; Ju,W.T.; Pickering, C.R.; Myers, J.N.; Zhang, Z.Y.; Zhong, L.P. Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma. BMC Cancer 2018, 18, 758.
19. Coutinho-Camillo, C.M.; Lourenço, S.V.; Nishimoto, I.N.; Kowalski, L.P.; Soares, F.A. Caspase expression in oral squamous cell carcinoma. Head Neck 2011, 33, 1191–1198.
20. Liu, P.F.; Hu, Y.C.; Kang, B.H.; Tseng, Y.K.; Wu, P.C.; Liang, C.C.; Hou, Y.Y.; Fu, T.Y.; Liou, H.H.; Hsieh, I.C.; et al. Expression levels of cleaved caspase-3 and caspase-3 in tumorigenesis and prognosis of oral tongue squamous cell carcinoma. PLoS ONE 2017, 12, e0180620.
2. Yu-Jen J, Chia-Der L, Chin-Ho L, Chih-Hsin T, Su-Hua H, Ming-Hsui T, et al. Salivary zinc finger protein 510 as a novel biomarker for detection of oral squamous cell carcinoma early stages. Clin Chim Acta. 2011 Jul 15; 412(15-16):1357-65.
3. Jou YJ, Lin CD, Lai CH, Chen CH, Kao JY, Chen SY, et al. Proteomic identification of salivary transferin as a biomarker for early detection of oral cancer. Anal Chim Acta. 2010 Nov 29; 681(1-2):41-8.
4. Nafisa Momeni. What is the treatment of oral Cancer? 1393. Available at: URL: http://www.dandane.ir/. Accessed Jan 10, 2017.
5. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nature reviews Molecular cell biology. 2005;6(5):376-85.
6. Lodish, H., et al. (2008). Molecular cell biology, Macmillan.
7. Chen J, Fu X, Wan Y, Wang Z, Jiang D, Shi L. miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. Tumour Biol. 2014;35 (7):6293–6302. doi:10.1007/s13277-014-1821-4.
8. Liu Z, Smith KR, Khong HT, et al. miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20. Oncotarget. 2016;7(48):78667–78679. doi:10.18632/oncotarget.12018.
9. Wang J, Paris PL, Chen J, et al. Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high gradeinvasive lesions. Cancer Lett. 2015;356(2):404-409.
10. Kandimalla R, Gao F, Matsuyama T, et al. Genome-wide discovery and identification of a novel miRNA signature for recurrence prediction in stage II and III colorectal cancer. Clin Cancer Res. 2018;24(16):3867-3877.
11. Gaziel-Sovran A, Segura MF, Di Micco R, et al. MiR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell. 2011;20(1):104-118
12. LI, C. I., URIBE, D. J., DALING, J. R. (2005). Clinical characteristics of different histologic types of breast cancer. British Journal of Cancer. 93(9), 1046-1052.
13. Pende, M., et al. (2004). "S6K1-/-/S6K2-/- mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogenactivated protein kinase-dependent S6 kinase pathway." Molecular and cellular biology 24(8): 3112-3124.
14. Sebolt-Leopold JS (June 2008). "Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway". Clin. Cancer Res. 14 (12): 3651–6. doi:10.1158/1078-0432.CCR-08-0333. PMID 18559577
15. Radhika T, Jeddy N, Nithya S, Muthumeenakshi RM. Salivary biomarkers in oral squamous cell carcinoma - An insight. J Oral Biol Craniofac Res. 2016 Nov;6(Suppl 1):S51-S54.
16. SUN, Yu-Meng; LIN, Kang-Yu; CHEN, Yue-Qin. Diverse functions of miR-125 family in different cell contexts. Journal of hematology & oncology, 2013, 6: 1-8.
17. Ghosh RD, Pattatheyil A, Roychoudhury S. Functional Landscape of Dysregulated MicroRNAs in Oral Squamous Cell Carcinoma: Clinical Implications. Front Oncol. 2020 May 12;10:619
18. Ma, J.; Fu, Y.; Tu, Y.Y.; Liu, Y.; Tan, Y.R.; Ju,W.T.; Pickering, C.R.; Myers, J.N.; Zhang, Z.Y.; Zhong, L.P. Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma. BMC Cancer 2018, 18, 758.
19. Coutinho-Camillo, C.M.; Lourenço, S.V.; Nishimoto, I.N.; Kowalski, L.P.; Soares, F.A. Caspase expression in oral squamous cell carcinoma. Head Neck 2011, 33, 1191–1198.
20. Liu, P.F.; Hu, Y.C.; Kang, B.H.; Tseng, Y.K.; Wu, P.C.; Liang, C.C.; Hou, Y.Y.; Fu, T.Y.; Liou, H.H.; Hsieh, I.C.; et al. Expression levels of cleaved caspase-3 and caspase-3 in tumorigenesis and prognosis of oral tongue squamous cell carcinoma. PLoS ONE 2017, 12, e0180620.
| Files | ||
| Issue | Vol 10, No 4 (Autumn 2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jcr.v10i4.15307 | |
| Keywords | ||
| oral squamous cell carcinoma miR-125 miR-30 biomarker | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Bahrami N, Poorahmad M, Hosseini F, Mohammadi F, Rasouli A, Mohajeri Tehrani M, Farhangiyan M, Mohamadnia A. Comparing Salivary Mir-125 And Mir-30 Expression In Oral Squamous Cell Carcinoma To Healthy Individuals. J Craniomaxillofac Res. 2024;10(4):162-166.
